Tools
Tools
Gillmore, JD, Reilly, MM, Coats, CJ, Cooper, R, Cox, H, Coyne, MRE, Green, AJ, McGowan, R, Moody, WE and Hawkins, PN (2022) Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK. Advances in Therapy, 39 (6). pp. 2292-2301. ISSN 0741-238X
|
Text
Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis.pdf - Published Version Available under License Creative Commons Attribution. Download (666kB) | Preview |
Abstract
Hereditary transthyretin-mediated amyloidosis (hATTR) is challenging to diagnose early owing to the heterogeneity of clinical presentation, which differs according to the TTR gene variant and its penetrance in each individual. The TTR variants seen most frequently in the UK and Ireland (T80A, V142I and V50M) differ to those commonly occurring in other geographic locations and warrant a specific consideration for diagnosis and genetic testing. In addition, recent availability of treatment for this condition has reinforced the need for a more consistent approach to the management of patients, including access to specialist services, genetic testing and counselling, and clinical investigation for families living in the UK and Ireland. A multidisciplinary panel of experts from the UK and Ireland was convened to identify the current challenges, provide recommendations, and develop a consensus for the diagnosis and screening of people with, or at risk of, hATTR. Over a series of meetings, experts shared their current practices and drafted, refined and approved a consensus statement. This consensus statement provides recommendations for three different groups: (1) people with symptoms raising a possibility of hATTR amyloidosis; (2) people with biopsy-confirmed hATTR amyloidosis; and (3) people without symptoms who may have hATTR amyloidosis (i.e. relatives of people with identified TTR variants). For each group, recommendations are made for the required steps for the diagnosis and follow-up of symptomatic patients, and for guidance on the specialist support for counselling and pre-symptomatic genetic testing of at-risk individuals. This guidance is intended to be practical and based on available evidence. The aim is for regional amyloid specialist centres to provide timely diagnosis, clinical screening, and treatment for individuals and their families with hATTR amyloidosis.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ATTR; Expert opinion; Genetic screening; Hereditary transthyretin amyloidosis; Amyloid Neuropathies, Familial; Expert Testimony; Humans; Ireland; Prealbumin; United Kingdom; General Clinical Medicine; 1115 Pharmacology and Pharmaceutical Sciences |
| Subjects: | Q Science > QH Natural history > QH426 Genetics R Medicine > R Medicine (General) |
| Divisions: | Sport & Exercise Sciences |
| Publisher: | Springer Science and Business Media LLC |
| SWORD Depositor: | A Symplectic |
| Date Deposited: | 24 Jun 2022 09:30 |
| Last Modified: | 24 Jun 2022 09:30 |
| DOI or ID number: | 10.1007/s12325-022-02139-9 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/17145 |
 |
View Item |